Canada Pension Plan Investment Board Buys 14,083 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Canada Pension Plan Investment Board increased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 12.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 130,100 shares of the company's stock after acquiring an additional 14,083 shares during the quarter. Canada Pension Plan Investment Board owned approximately 0.16% of IDEXX Laboratories worth $53,789,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Hurley Capital LLC bought a new stake in IDEXX Laboratories during the fourth quarter worth $29,000. Rialto Wealth Management LLC bought a new stake in shares of IDEXX Laboratories in the fourth quarter valued at $30,000. Retirement Wealth Solutions LLC bought a new stake in shares of IDEXX Laboratories in the fourth quarter valued at $31,000. Kestra Investment Management LLC bought a new stake in shares of IDEXX Laboratories in the fourth quarter valued at $38,000. Finally, Crews Bank & Trust bought a new stake in shares of IDEXX Laboratories in the fourth quarter valued at $41,000. 87.84% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on IDXX. Morgan Stanley reduced their price target on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a research report on Wednesday, January 29th. Bank of America lifted their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research report on Tuesday, February 4th. Stifel Nicolaus reduced their price target on IDEXX Laboratories from $450.00 to $420.00 and set a "hold" rating for the company in a research report on Monday, April 14th. StockNews.com cut IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Saturday, April 12th. Finally, Piper Sandler boosted their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research report on Monday, February 10th. Four analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $523.75.

Insider Transactions at IDEXX Laboratories

In other news, Director M Anne Szostak sold 3,000 shares of the business's stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the sale, the director now owns 3,061 shares of the company's stock, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP George Fennell sold 9,986 shares of the business's stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares of the company's stock, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.98% of the company's stock.

IDEXX Laboratories Price Performance

Shares of IDXX traded up $10.98 during midday trading on Thursday, reaching $437.61. The stock had a trading volume of 278,362 shares, compared to its average volume of 627,969. The company's 50-day moving average is $420.23 and its 200 day moving average is $429.89. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $548.88. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. The company has a market capitalization of $35.46 billion, a price-to-earnings ratio of 41.02, a price-to-earnings-growth ratio of 3.41 and a beta of 1.50.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.